Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will utilize a retrospective cohort design. Using the Clinical Practice Research Datalink (CPRD) linked with Hospital Episode Statistics (HES) datasets, all patients with a record of VTE diagnosis between 1 April, 2008 and 31 March, 2013 will be identified and followed from the occurrence of VTE (index date) to the first of 24 months after the index date, end of the study period, leaving the database, or death.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Population with condition and with exposure |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Anticoagulation treatment patterns for patients following acute Venous Thromboembolism (VTE) based on all VTE events that occur during the study period | Anticoagulation treatment pattern includes type of anticoagulant (AC), duration of AC treatment, switching between ACs and switching from AC to aspirin or other antiplatelet agents (APA). | up to 24 months following VTE occurrence |
| Measure | Description | Time Frame |
|---|---|---|
| Demographic characteristics (age, gender) of patients with acute VTE | up to 24 months following VTE occurrence | |
| Clinical characteristics (comorbidities, concomitant treatments, medical and surgical history) of patients with acute VTE | up to 24 months following VTE occurrence |
Not provided
Inclusion Criteria:
VTE events will be included if:
Exclusion Criteria:
VTE events will be excluded if:
Not provided
Not provided
Not provided
Primary care clinic, community sample and residents of a community
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bristol-Myers Squibb | Bristol-Myers Squibb | Study Director |
Not provided
Not provided
Not provided
Not provided
Not provided
| Rates of unplanned (emergency) hospital admission, major surgery, major bleeding, and VTE recurrence | up to 24 months following VTE occurrence |
| Baseline demographic and clinical characteristics associated with the duration of AC treatment after VTE | up to 24 months following VTE occurrence |
| Baseline demographic and clinical characteristics associated with novel oral anticoagulant (NOAC) treatment compared with vitamin K antagonist (VKA) treatment following VTE | up to 24 months following VTE occurrence |
| ID | Term |
|---|---|
| D054556 | Venous Thromboembolism |
| ID | Term |
|---|---|
| D013923 | Thromboembolism |
| D016769 | Embolism and Thrombosis |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided